Research programme: anti-fungals - Elitra

Drug Profile

Research programme: anti-fungals - Elitra

Alternative Names: Anti-fungals research programme - Elitra

Latest Information Update: 19 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concordia University; Elitra Canada (CEASED); McGill University; Natural Sciences and Engineering Research Council of Canada; University of Toronto
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 19 Apr 2007 Discontinued - Preclinical for Mycoses in Canada (unspecified route)
  • 02 Jul 2002 This programme is still in active development
  • 22 Dec 2000 Mycota Biosciences has been acquired by Elitra Pharmaceuticals and renamed Elitra Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top